Business Directories

Leading Emirati pharmaceutical firm Julphar has acquired a majority stake in Bangladesh-based RAK Pharmaceuticals, as part of its expansion plans in Asia, according to a report.
RAK Pharmaceuticals is a subsidiary of RAK Ceramics

Global pharmaceutical companies are beginning to transfer knowledge to local manufacturing partners in the UAE, encouraged by supportive government policies and a strong regulatory framework.
This is helping the Emirates’ to

The Western world's first gene therapy drug is set to go on sale in Germany with a 1.1 million euro ($1.4 million) price tag, a new record for a medicine to treat a rare disease.
The sky-high cost of Glybera, from Dutch biotec

Julphar, a leading UAE-based pharmaceutical firm, has announced plans to recruit 60 Emiratis every year to reach a total of 300 over the next five years.
The move comes as part of the company's commitment to &ls

Julphar, a leading UAE-based pharmaceutical firm, has announced plans to recruit 60 Emiratis every year to reach a total of 300 over the next five years.
The move comes as part of the company's commitment to &ls

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has entered into a tripartite agreement for local production in Saudi Arabia with Cigalah and Tabouk.
The move came from Boehringer Ingelheim’s

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has entered into a tripartite agreement for local production in Saudi Arabia with Cigalah and Tabouk.
The move came from Boehringer Ingelheim’s

The pharmaceutical market in Saudi Arabia including government procurements is estimated at SR13.5 billion ($3.6 billion) with the private sector claiming a share of SR7 billion, a report said.
The per capita consumption of medici

Boehringer Ingelheim, a research-driven pharmaceutical company, has achieved a growth of 14 per cent in the Mena region in the last fiscal year.
Despite some challenges, the company succeeded in increasing its operating income and

Saudi Arabia’s oil-fueled prosperity, growing population and liberal health spending policies are major drivers of market growth and has generated opportunities for multinational pharmaceutical companies, said a report.
The